» Articles » PMID: 35312728

Variation in CFTR-dependent 'β-sweating' Among Healthy Adults

Overview
Journal PLoS One
Date 2022 Mar 21
PMID 35312728
Authors
Affiliations
Soon will be listed here.
Abstract

The genetic disease cystic fibrosis (CF) results when mutations in the gene for the anion channel CFTR reduce CFTR's activity below a critical level. CFTR activity = N·PO·γ (number of channels x open probability x channel conductance). Small molecules are now available that partially restore CFTR function with dramatic improvements in health of CF subjects. Continued evaluation of these and other compounds in development will be aided by accurate assessments of CFTR function. However, measuring CFTR activity in vivo is challenging and estimates vary widely. The most accurate known measure of CFTR activity in vivo is the 'β/M' ratio of sweat rates, which is produced by stimulation with a β-adrenergic agonist cocktail referenced to the same individual's methacholine-stimulated sweat rate. The most meaningful metric of CFTR activity is to express it as a percent of normal function, so it is critical to establish β/M carefully in a population of healthy control subjects. Here, we analyze β/M from a sample of 50 healthy adults in which sweat rates to cholinergic and β-adrenergic agonists were measured repeatedly (3 times) in multiple, (~50) identified sweat glands from each individual (giving ~20,000 measurements). The results show an approximately 7-fold range, 26-187% of the WT average set to 100%. These provide a benchmark against which other measures of CFTR activity can be compared. Factors contributing to β/M variation in healthy controls are discussed.

References
1.
Quinton P, Molyneux L, Ip W, Dupuis A, Avolio J, Tullis E . β-adrenergic sweat secretion as a diagnostic test for cystic fibrosis. Am J Respir Crit Care Med. 2012; 186(8):732-9. DOI: 10.1164/rccm.201205-0922OC. View

2.
Cuppens H, Lin W, Jaspers M, Costes B, Teng H, Vankeerberghen A . Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. J Clin Invest. 1998; 101(2):487-96. PMC: 508589. DOI: 10.1172/JCI639. View

3.
Miller A, Comellas A, Hornick D, Stoltz D, Cavanaugh J, Gerke A . Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. Proc Natl Acad Sci U S A. 2019; 117(3):1621-1627. PMC: 6983448. DOI: 10.1073/pnas.1914912117. View

4.
Delaney S, Rich D, Thomson S, Hargrave M, Lovelock P, Welsh M . Cystic fibrosis transmembrane conductance regulator splice variants are not conserved and fail to produce chloride channels. Nat Genet. 1993; 4(4):426-31. DOI: 10.1038/ng0893-426. View

5.
Wine J, Joo N, Choi J, Cho H, Krouse M, Wu J . Measurement of fluid secretion from intact airway submucosal glands. Methods Mol Biol. 2011; 742:93-112. DOI: 10.1007/978-1-61779-120-8_6. View